JVJennifer Rabke Verani

Jennifer Rabke Verani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jennifer Rabke Verani has a total of 316 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel R. Feikin

    Division of Global Health Protection, Centre for Global Health, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    4 shared publications
  • Allan Audi

    Kenya Medical Research Institute-Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya

    3 shared publications
  • Bryan O. Nyawanda

    Swiss Tropical and Public Health Institute

    3 shared publications
  • Clayton Onyango

    Division of Global Health Protection, Centre for Global Health, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    3 shared publications
  • Cynthia G. Whitney

    Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, N.E. Atlanta, GA 30333, United States; Rollins School of Public Health, Emory University, 1518 Clifton Rd, Atlanta, GA 30322, United States

    3 shared publications
  • Elizabeth Hunsperger

    Division of Global Health Protection, Centre for Global Health, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    3 shared publications

Latest Publications

  • Open Access

    Population-based incidence and antimicrobial susceptibility patterns of shigellosis among children and adults from rural and urban Kenya, 2010–2019

    by Richard Omore, Billy Ogwel, John B. Ochieng, Jane Juma, Victor Omballa, Alice Ouma, George Aol, Allan Audi, George O. Agogo, George Odongo, et al.

    Backgroun: Shigella is an important cause of diarrheal morbidity and mortality globally. Data on disease burden across age groups, in different epidemiologic settings, and over time are needed to guide preventive strategies. We examined shigellosis in two sites in Kenya over a 10-year period. Methods: We used data from the Population-Based Infectious Disease Surveillance (PBIDS) platform in a rural (Asembo, population ~35,000) and urban (Kibera, population ~23,000) setting. PBIDS participants presenting to surveillance clinics with diarrhea (≥3 loose stools in 24-hour period) had stool collected and cultured; Shigella isolates underwent antimicrobial susceptibility testing. We estimated incidence by dividing Shigella cases by person-years- observation, adjusting for the proportion of diarrhea cases with stool collected and for care-seeking outside surveillance clinics. Results: From January 1, 2010 to December 31, 2019, we isolated Shigella from 23% and 15% of 2,017 and 4,074 stool specimens collected in Asembo and Kibera, respectively; S. flexneri accounted for 61% and 67%, respectively. In Asembo, the adjusted shigellosis incidence was 684/100,000; it was highest in ages 12–23 months (1,873/100,000) and ≥50 years (1,502/100,000). In Kibera, the adjusted incidence was 647/100,000, highest in ages 12–23 (2,828/100,000) and 24–59 months (936/100,000). Incidence declined significantly in Asembo (p = 0.009), but not in Kibera (p = 0.53). Overall, ≥ 97% of isolates were susceptible to ciprofloxacin and ceftriaxone. Conclusion: The shigellosis burden was greatest among young toddlers in both urban and rural areas and was high among older adults in the rural setting. Although resistance to first-line antibiotics was infrequent, continued susceptibility monitoring is warranted.


  • Open Access

    Population-based incidence and antimicrobial susceptibility patterns of shigellosis among children and adults from rural and urban Kenya, 2010-2019

    by Richard Omore, Billy Ogwel, John B. Ochieng, Jane Juma, Victor Omballa, Alice Ouma, George Aol, Allan Audi, George O. Agogo, George Odongo, et al.

    Background: Shigella is an important cause of diarrheal morbidity and mortality globally. Data on disease burden across age groups, in different epidemiologic settings, and over time are needed to guide preventive strategies. We examined shigellosis in two sites in Kenya over a 10-year period. Methods: We used data from the Population-Based Infectious Disease Surveillance (PBIDS) platform in a rural (Asembo, population ∼35,000) and urban (Kibera, population ∼23,000) setting. PBIDS participants presenting to surveillance clinics with diarrhea (≥3 loose stools in 24-hour period) had stool collected and cultured; Shigella isolates underwent antimicrobial susceptibility testing. We estimated incidence by dividing Shigella cases by person-years-observation, adjusting for the proportion of diarrhea cases with stool collected and for care-seeking outside surveillance clinics. Results: From January 1, 2010 to December 31, 2019, we isolated Shigella from 23% and 15% of 2,017 and 4,074 stool specimens collected in Asembo and Kibera, respectively; S. flexneri accounted for 61% and 67%, respectively. In Asembo, the adjusted shigellosis incidence was 684/100,000; it was highest in ages 12-23 months (1,873/100,000) and ≥50 years (1,502/100,000). In Kibera, the adjusted incidence was 647/100,000, highest in ages 12-23 (2,828/100,000) and 24-59 months (936/100,000). Incidence declined significantly in Asembo (p=0.009), but not in Kibera (p=0.53). Overall, ≥97% of isolates were susceptible to ciprofloxacin and ceftriaxone. Conclusion: The shigellosis burden was greatest among young toddlers in both urban and rural areas and was high among older adults in the rural setting. Although resistance to first-line antibiotics was infrequent, continued susceptibility monitoring is warranted. Summary: Children 12-23 months old bear the greatest burden of Shigella disease; Shigella isolates remain largely susceptible to ciprofloxacin in both rural and urban Kenya.

  • Open Access

    Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalence

    by Katherine E. Gallagher, Fredrick Odiwour, Christian Bottomley, John Ojal, Aisha Adamu, Esther Muthumbi, Eunice W. Kagucia, Laura L Hammitt, Sergio Massora, Betuel Sigaúque, et al.

    Background: Serotype-specific estimates of pneumococcal invasiveness used in pneumococcal carriage transmission models to predict changes in disease incidence post-vaccination are largely derived from high-income settings. We conducted a systematic review of carriage prevalence and invasive pneumococcal disease (IPD) incidence to calculate case-carrier ratios (CCRs) in different income settings. Methods: A systematic search of Medline, Embase, and Global Health databases in March 2022 identified publications on pneumococcal carriage prevalence or IPD incidence; we requested individual-level data from authors of relevant texts. Serotype-specific CCRs, calculated as IPD incidence divided by carriage prevalence, were pooled across settings using random effects meta-analyses, stratified by pre-/post-pneumococcal conjugate vaccine (PCV) introduction, country income group, age-group, sex and HIV status. Findings: We identified 80 publications from 18 countries (13 upper-middle- or high-income countries (UM/HIC), 5 low/lower-middle income (L/LMIC)) reporting carriage prevalence or IPD incidence in overlapping geographical areas, time periods, and age-groups. We calculated CCRs for >70 serotypes, stratified by age group, income settings, and pre- and post-vaccine introduction. In children under five, pre-PCV CCRs for serotypes not included in the 20-valent PCV were higher in L/LMICs than UM/HICs, 152 (95% Confidence interval 103-226) versus 102 (50-209). Post-PCV CCRs for non-vaccine serotypes dropped in UM/HICs but not in L/LMICs, 19 (16-22) versus 154 (119-200) respectively. Pre-/post PCV changes varied by serotype and age-group. CCRs were lowest in 5–14-year-olds and were higher in HIV positive than HIV negative individuals. There were no differences in CCRs by sex. Interpretation: Pneumococcal invasiveness varies by serotype, age-group, country income-group, HIV status and over time; however, substantial variation remained unexplained. Our CCRs represent the most representative estimates of invasiveness currently available for use in statistical or mathematical prediction models of disease incidence, where only carriage prevalence data are available. Funding: The Wellcome Trust, Great Britain (098532) Panel: Research in context: Evidence before this study: There are three estimates of the absolute risk of invasive pneumococcal disease, given carriage, derived from data from high-income settings (two studies in the UK, and one in the USA). A fourth set of estimates have been derived from data collated by a recent review of studies that reported both carriage and IPD data in the same publication. This review and re-analysis combined data from 12 countries to report case-carrier ratios in children under-5, pre- and post-vaccine introduction. The review did not include data from IPD surveillance sites in low- and middle-income countries, nor carriage prevalence data in adults. Added value of this study: We conducted an extensive systematic review to identify high quality IPD incidence estimates and a comprehensive database of carriage prevalence estimates that arise from the same country, age-group and time period as these IPD incidence estimates. We employed stringent matching criteria to only include the results of carriage surveys that were conducted in a random sample of the general population, and IPD surveillance activities that were conducted in a systematic way across a defined population. This enabled us to estimate serotype-specific pneumococcal case-carrier ratios, stratified by age group, country income group, and time period pre- or post-vaccine introduction. Implications of all the available evidence: Invasive pneumococcal disease surveillance is resource intensive to establish and sustain and is therefore infeasible for most countries worldwide. Pneumococcal vaccine policy is often made on the basis of carriage data alone, or mathematical models which predict changes in disease incidence by combining changes in carriage prevalence with pre-specified case-carrier ratios. We have used all available data globally to estimate serotype-specific case-carrier ratios, which previously have been derived from data from high income settings. Both statistical and mathematical models predicting changes in disease incidence in low-income settings, can now utilise case-carrier ratios from more relevant population groups. This will be of increasing importance as policy makers attempt to make evidence-based decisions on whether to change pneumococcal vaccine product, schedule, or simply increase coverage of the existing programme.


  • Open Access

    Acute febrile illness in Kenya: Clinical characteristics and pathogens detected among patients hospitalized with fever, 2017–2019

    by Jennifer R. Verani, Eric Ng’ Eno, Elizabeth A. Hunsperger, Peninah Munyua, Eric Osoro, Doris Marwanga, Godfrey Bigogo, Derrick Amon, Melvin Ochieng, Paul Etau, et al.

    Acute febrile illness (AFI) is a common reason for healthcare seeking and hospitalization in Sub-Saharan Africa and is often presumed to be malaria. However, a broad range of pathogens cause fever, and more comprehensive data on AFI etiology can improve clinical management, prevent unnecessary prescriptions, and guide public health interventions. We conducted surveillance for AFI (temperature ≥38.0°C Plasmodium, as a single pathogen in 471 (35.8%) cases and in combination with other pathogens in 38 (2.9%). HIV was detected in 51 (3.8%) UF cases tested by TAC and was most common in adults (25/236 [10.6%] ages 18–49, 4/40 [10.0%] ages ≥50 years). Chikungunya virus was found in 30 (2.3%) UF cases, detected only in the Mombasa site. Malaria prevention and control efforts are critical for reducing the burden of AFI, and improved diagnostic testing is needed to provide better insight into non-malarial causes of fever. The high case fatality of AFI underscores the need to optimize diagnosis and appropriate management of AFI to the local epidemiology.


  • Open Access

    Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction

    by Jennifer R. Verani, Daniel Omondi, Arthur Odoyo, Herine Odiembo, Alice Ouma, Juliet Ngambi, George Aol, Allan Audi, Samwel Kiplangat, Noel Agumba, et al.


  • Open Access

    Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study

    by Kristin L. Andrejko, Ryan Gierke, Jemma V. Rowlands, Jennifer B. Rosen, Ann Thomas, Zachary Q. Landis, Maria Rosales, Sue Petit, William Schaffner, Corinne Holtzman, et al.


  • Top Cited Papers
    Open Access

    Child deaths caused by Klebsiella pneumoniae in sub-Saharan Africa and south Asia: a secondary analysis of Child Health and Mortality Prevention Surveillance (CHAMPS) data

    by Jennifer R Verani, Dianna M Blau, Emily S Gurley, Victor Akelo, Nega Assefa, Vicky Baillie, Quique Bassat, Mussie Berhane, James Bunn, Anelsio C A Cossa, et al.


  • Open Access

    Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil

    by Joice Neves Reis, Jailton Azevedo, Aisla Mércia Lazaro de Oliveira, Ana Paula de Oliveira Menezes, Mayara Pedrosa, Milena Soares dos Santos, Laise Carvalho Ribeiro, Humberto Fonseca de Freitas, Edilane Lins Gouveia, Marcelo Bastos Teles, et al.


  • Open Access

    Point-prevalence survey of antibiotic use at three public referral hospitals in Kenya

    by Sylvia Omulo, Margaret Oluka, Loice Achieng, Eric Osoro, Rosaline Kinuthia, Anastasia Guantai, Sylvia Adisa Opanga, Marion Ongayo, Linus Ndegwa, Jennifer R. Verani, et al.

    Antimicrobial stewardship encourages appropriate antibiotic use, the specific activities of which will vary by institutional context. We investigated regional variation in antibiotic use by surveying three regional public hospitals in Kenya. Hospital-level data for antimicrobial stewardship activities, infection prevention and control, and laboratory diagnostic capacities were collected from hospital administrators, heads of infection prevention and control units, and laboratory directors, respectively. Patient-level antibiotic use data were abstracted from medical records using a modified World Health Organization point-prevalence survey form. Altogether, 1,071 consenting patients were surveyed at Kenyatta National Hospital (KNH, n = 579), Coast Provincial General Hospital (CPGH, n = 229) and Moi Teaching and Referral Hospital (MTRH, n = 263). The majority (67%, 722/1071) were ≥18 years and 53% (563/1071) were female. Forty-six percent (46%, 489/1071) were receiving at least one antibiotic. Antibiotic use was higher among children P < 0.001). Critical care (82%, 14/17 patients) and pediatric wards (59%, 155/265) had the highest proportion of antibiotic users. Amoxicillin/clavulanate was the most frequently used antibiotic at KNH (17%, 64/383 antibiotic doses), and ceftriaxone was most used at CPGH (29%, 55/189) and MTRH (31%, 57/184). Forty-three percent (326/756) of all antibiotic prescriptions had at least one missed dose recorded. Forty-six percent (204/489) of patients on antibiotics had a specific infectious disease diagnosis, of which 18% (37/204) had soft-tissue infections, 17% (35/204) had clinical sepsis, 15% (31/204) had pneumonia, 13% (27/204) had central nervous system infections and 10% (20/204) had obstetric or gynecological infections. Of these, 27% (56/204) had bacterial culture tests ordered, with culture results available for 68% (38/56) of tests. Missed antibiotic doses, low use of specimen cultures to guide therapy, high rates of antibiotic use, particularly in the pediatric and surgical population, and preference for broad-spectrum antibiotics suggest antibiotic use in these tertiary care hospitals is not optimal. Antimicrobial stewardship programs, policies, and guidelines should be tailored to address these areas.


  • Open Access

    Comparable Pregnancy Outcomes for HIV-Uninfected and HIV-Infected Women on Antiretroviral Treatment in Kenya

    by Cyrus Mugo, Ruth Nduati, Eric Osoro, Bryan O Nyawanda, Harriet Mirieri, Elizabeth Hunsperger, Jennifer R Verani, Hafsa Jin, Dufton Mwaengo, Brian Maugo, et al.

    The impact of human immunodeficiency virus (HIV) on pregnancy outcomes for women on antiretroviral therapy (ART) in sub-Saharan Africa remains unclear. Pregnant women in Kenya were enrolled in the second trimester and followed up to delivery. We estimated effects of treated HIV with 3 pregnancy outcomes: loss, premature birth, and low birth weight and factors associated with HIV-positive status. Of 2113 participants, 311 (15%) were HIV infected and on ART. Ninety-one of 1762 (5%) experienced a pregnancy loss, 169/1725 (10%) a premature birth (P = .57), prematurity (aRR, 1.09; 95% CI, .70–1.70; P = .69), and low birth weight (aRR, 1.36; 95% CI, .77–2.40; P = .27). Factors associated with an HIV-positive status included older age, food insecurity, lower education level, higher parity, lower gestation at first antenatal clinic, anemia, and syphilis. Women who were overweight or underweight were less likely to be HIV infected compared to those with normal weight. Currently treated HIV was not significantly associated with adverse pregnancy outcomes. HIV-infected women, however, had a higher prevalence of other factors associated with adverse pregnancy outcomes.